Scleroderma Newsroom
ISN News Manager: Jo Frowde
Media Stories
Scleroderma Archive
We maintain news archives for the most recent 3 years.
2019: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2021 - 2020 - 2019 - 2018

October 2019 Scleroderma News

Increased prevalence of small airways dysfunction in patients with systemic sclerosis (SSc) as determined by impulse oscillometry. A full assessment of lung function in SSc patients should include impulse oscillometry as a complementary technique, due to potential clinical and therapeutic implications. PubMed, Rheumatology (Oxford), 08/22/2019. (Also see Pulmonary Fibrosis Diagnosis)

Potential Cannabidiol Treatment EHP-101 Shows Safety in Early Trial, Study in Scleroderma Patients Being Readied. EHP-101, an oral cannabidiol treatment candidate for people with scleroderma (SSc) and multiple sclerosis (MS), was found to be safe and well-tolerated in a Phase 1 clinical trial in healthy volunteers. Scleroderma News, 08/28/2019. (Also see Endocannabinoid System)

Revised European Scleroderma (SSc) Trials and Research Group Activity Index is the best predictor of short-term severity accrual. The adjusted mean EUSTAR-AI has the best predictive value for disease progression and development of severe organ involvement over time in SSc. PubMed, Ann Rheum Dis, 08/17/2019. (Also see Prognosis and Mortality)

Vasodilators and low-dose acetylsalicylic acid (ASA) are associated with a lower incidence of distinct primary myocardial disease manifestations in systemic sclerosis: results of the DeSScipher inception cohort study. The present study might suggest a preventative effect on the occurrence of distinct myocardial manifestations by vasodilator therapy and low-dose ASA. PubMed, Ann Rheum Dis, 08/07/2019. (Also see Treatments for Systemic Scleroderma Heart Involvement)

A multicenter randomized, double-blind, placebo-controlled pilot study to assess the efficacy and safety of riociguat in systemic sclerosis-associated digital ulcers (SSc-DU). In participants with SSc-DU, treatment with riociguat did not reduce the number of DU net burden compared with placebo at 16 weeks. PubMed, Arthritis Res Ther, 2019 Sep 3;21(1):202. (Also see Treatments for Digital Ulcers and Clinical Trials: Completed, Negative Results)

Ethnic Variations in Systemic Sclerosis (SSc) Disease Manifestations, Internal Organ Involvement, and Mortality. Ethnic variations in some SSc disease manifestations are observed, but this does not result in significant differences in short-term survival but may affect long-term survival. PubMed, J Rheumatol, 2019 Sep;46(9):1103-1108. (Also see Ethnicity, Race and Geographical Regions)

Health-related quality of life (HRQoL) in systemic sclerosis (SSc) before and after autologous haematopoietic stem cell transplant (AHSCT) - a systematic review. AHSCT in severe SSc patients is associated with significant and durable improvement in physical HRQoL. PubMed, Rheumatology (Oxford), 08/27/2019. (Also see Stem Cell Transplantation and Quality of Life)

Case Report: Total gastrectomy in systemic scleroderma when anti-reflux surgery is not viable. We suggest an open gastrectomy with roux-en-Y anastomosis as an alternative to the Nissen fundoplication for patients with connective tissue disease. PubMed, Int J Surg Case Rep. (Also see Reflux (Heartburn) Prevention and Treatments)

Increased expression of GAB1 promotes inflammation and fibrosis in systemic sclerosis (SSc). This data suggests that GAB1 has a relatively high expression rate in SSc, and knockdown of GAB1 may attenuate SSc by stimulating inflammatory and fibrotic processes. PubMed, Exp Dermatol, 09/10/2019. (Also see Prognosis and Mortality and Skin Fibrosis)

The Relationship Between Autonomic Dysfunction of the Gastrointestinal (GI) Tract and Emotional Distress in Patients With Systemic Sclerosis (SSc). In SSc, increased symptom burden related to GI dysautonomia is associated with emotional distress. PubMed, J Clin Rheumatol, 09/12/2019. (Also see Bowel Dysfunction and Coping with Scleroderma)

Go to Scleroderma Medical News: September 2019

SCLERO.ORG is the world's leading nonprofit for trustworthy research, support, education and awareness for scleroderma and related illnesses. We are a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team. Donations may also be mailed to:

International Scleroderma Network (ISN)
7455 France Ave So #266
Edina, MN 55435-4702 USA
Email [email protected]. Disclaimer. Privacy Policy.